Asceneuron aims to address high unmet medical needs in neurodegenerative proteinopathies such as orphan tauopathies, Alzheimer’s and Parkinson’s disease. Our pipeline is composed of innovative small-molecule therapeutics aiming to prevent disease progression in proteinopathies and reverse cognitive impairment in dementia.
AD: Alzheimer's disease
LBD: Lewy Body Dementia
FTD: Frontotemporal dementia
PDD: Parkinson's disease dementia
PSP: Progressive Supranuclear Palsy
About ASN90
Asceneuron’s most advanced program ASN90 (formerly labelled as ASN120290 or ASN-561) is an OGA inhibitor which is being developed for the orphan tau-related disease, progressive supranuclear palsy (PSP), after receiving orphan drug designation by the US FDA and the European EMA for the treatment of PSP. ASN90 has completed three clinical studies in healthy volunteers including a randomized, double-blind, placebo-controlled phase I study to assess its safety and tolerability of single and multiple doses in healthy young and elderly volunteers and a human positron emission tomography (PET) CNS target engagement study.
About ASN51
Asceneuron’s next generation OGA inhibitor ASN51 was awarded USD 2.2 million from the Alzheimer’s Drug Discovery Foundation for a first in human Phase I study. ASN51 has completed two clinical studies in healthy volunteers including a randomized, double-blind, placebo-controlled phase I study to assess its safety and tolerability of single and multiple doses in healthy young and elderly volunteers and a human positron emission tomography (PET) CNS target engagement study. A third biomarker-centric trial currently recruits Alzheimer's disease patients.
